The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

16 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease.EBI
University of South Carolina
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.EBI
University of South Carolina
Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.EBI
University of South Carolina
Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.EBI
University of South Carolina
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.EBI
University of South Carolina
Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine.EBI
University of South Carolina
Development of fluorophore labeled or biotinylated anticancer small molecule NSC243928.EBI
University of South Carolina
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.EBI
University of South Carolina
A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.EBI
University of South Carolina
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.EBI
University of South Carolina
Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.EBI
University of South Carolina
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.EBI
University of South Carolina
Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.EBI
University of South Carolina
Synthesis and cholinergic properties of N-aryl-2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethylamino analogs of ranitidine.EBI
University of South Carolina
PI-kinase inhibitors with anti-infective activityBDB
University of California
Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.BDB
Johnson & Johnson Pharmaceutical Research and Development